Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

Who May Qualify: - Patient aged 35 or over - Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period - With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 \& 5 on LDLR, APOB or PCSK9 - Patient not objecting to inclusion in study (no written objection) Who Should NOT Join This Trial: - Protected patients: minors, adults under guardianship, curatorship and/or safeguard of justice - Pregnant or breast-feeding - Active viral hepatitis - Hemochromatosis - Other genetic or autoimmune hepatitis - Current treatment with a drug likely to cause hepatic steatosis, including amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals - Current oral corticosteroid therapy unless dose has been stable for ≥ 3 months - Current pathological alcohol consumption (≥ 60 g/day in men and ≥ 50 g/day in women) Always talk to your doctor about whether this trial is right for you.